Sudden Cardiac ArrestRESOUDRENCT06642168
Sudden Cardiac Arrest Related to Sport in Young and Value of the Genetic Assessment: a French Prospective Register
An observational study of Sudden Cardiac Arrest and Sudden Cardiac Death, run by Rennes University Hospital at 26 sites in France.
Trial summary
The increased risk of sudden cardiac arrest (SCA) or sudden cardiac death (SCD) related to vigorous physical activity is well-documented. Currently, for young victims (under 35 years) of SCA/SCD, no etiology is found in 40 to 50% of cases after a standard medical assessment, leading to two important consequences. Read more about this study
- Who is it for?
- Ages 12 to 35 years
- Conditions the study is for
- Sudden Cardiac Arrest, Sudden Cardiac Death
- What is being tested?
- Whole exome sequencing to detect myocardial genetic mutations (SCA group only)
- How many people
- 80 participants
- Where
- 26 sitesFrance
- Study dates
- 11 Oct 2024to 11 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 35 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: The study will include French victims of sports-related SCA/SCD between the ages of 12 and 35, as well as their first-degree relatives over 12 years of age, when applicable.
Who may be able to join
- Victims of SCA:
- Aged between 12 and 35 years
- No known cardiovascular pathology
- Experienced a sudden and non-traumatic SCA during or within one hour of participating in sports activities (leisure, training, or competition)
- For resuscitated victims (SCA group): A person or legal representative who does not oppose participation in the research after being informed about the study (including individuals, organs, or authorities responsible for assisting or representing them if they are unable to express their wishes).
- For non-resuscitated victims (SCD group): A person who has not formally objected to the reuse of their medical data during their lifetime.
Show all 11Show fewer
- First-Degree Relatives:
- A person or legal representative who does not oppose participation in the research after being informed about the study (including individuals, bodies, or authorities responsible for assisting or representing them if they are unable to express their wishes).
- Non-Inclusion Criteria:
- For resuscitated SCA cases, individuals weighing less than 20 kg
- Victims or legal representatives who are subject to legal protection or deprived of their liberty
Who cannot join
None listed.
Trial locations and contacts
26 sites in 1 country. Contact the study team or a site near you to ask about taking part.
26 sites in 1 country
France26 sites, 26 recruiting
- Recruiting
CHU Bordeaux
Bordeaux, 33600
Frédéric SACHER, frederic.sacher@chu-bordeaux.fr
Frédéric SACHER
- Not yet recruiting
CHU Brest
Brest, 29609
Jacques MANSOURATI, jacques.mansourati@chu-brest.fr
Jacques MANSOURATI
- Recruiting
CHU Caen
Caen, 14033
Amir HODZIC, hodzic-a@chu-caen.fr
Amir HODZIC
- Recruiting
CHU Clermont-Ferrand
Clermont-Ferrand, 63003
Romain ESCHALIER, reschalier@chu-clermontferrand.fr
Romain ESCHALIER
- Not yet recruiting
APHP Hôpital Henri-Mondor
Créteil, 94010
Nicolas LELLOUCHE, nicolas.lellouche@aphp.fr
Nicolas LELLOUCHE
- Not yet recruiting
CHU Dijon Bourgogne
Dijon, 21079
Gabriel LAURENT, gabriel.laurent@chu-dijon.fr
Gabriel LAURENT
- Not yet recruiting
CHU de Grenoble Alpes
Grenoble, 38700
Pascal DEFAYE, PDefaye@chu-grenoble.fr
Pascal DEFAYE
- Recruiting
CHRU Lille
Lille, 59037
Didier KLUG, Didier.KLUG@chu-lille.fr
Didier KLUG
- Not yet recruiting
Hospices Civils de Lyon
Lyon, 69229
Philippe CHEVALIER, philippe.chevalier@chu-lyon.fr
Philippe CHEVALIER
- Recruiting
APHM Hôpitaux universitaires de Marseille
Marseille, 13364
Jean-Claude DEHARO, JeanClaude.DEHARO@ap-hm.fr
Jean-Claude DEHARO
- Recruiting
CHRU Montpellier
Montpellier, 34295
Jean-Luc PASQUIE, jl-pasquie@chu-montpellier.fr
Jean-Luc PASQUIE
- Not yet recruiting
CHRU Nancy
Nancy, 54035
Etienne ALIOT, E.ALIOT@chru-nancy.fr
Etienne ALIOT
- Recruiting
CHU Nantes
Nantes, 44093
Vincent PROBST, vincent.probst@chu-nantes.fr
Vincent PROBST
- Recruiting
CHU de Nice
Nice, 06003
Didier SCARLATTI, scarlatti.d@chu-nice.fr
Didier SCARLATTI
- Not yet recruiting
CHU Nîmes
Nîmes, France, 30029
Camille SOULLIER, camille.SOULLIER@chu-nimes.fr
Camille SOULLIER
- Not yet recruiting
APHP Hôpital Bichat
Paris, France, 75877
Fabrice EXTRAMIANA, fabrice.extramiana@aphp.fr
Fabrice EXTRAMIANA
- Recruiting
APHP Hôpital Européen Georges Pompidou
Paris, France, 75908
Eloi MARIJON, eloi.marijon@aphp.fr
Eloi MARIJON
- Recruiting
APHP Hôpital Pitié-Salpêtrière
Paris, 75651
Estelle GANDJBAKHCH, estelle.gandjbakhch@aphp.fr
Estelle GANDJBAKHCH
- Recruiting
CHU Poitiers
Poitiers, 86000
Rodrigue GARCIA, rodrigue.garcia@chu-poitiers.fr
Rodrigue GARCIA
- Not yet recruiting
CHU Reims
Reims, 51092
François LESAFFRE, flesaffre@chu-reims.fr
François LESAFFRE
- Recruiting
CHU Rennes
Rennes, France, 35000
Frédéric SCHNELL, frederic.schnell@chu-rennes.fr
Frédéric SCHNELL
- Not yet recruiting
CHU Rouen
Rouen, 76031
Frédéric ANSELME, Frederic.Anselme@chu-rouen.fr
Frédéric ANSELME
- Recruiting
CHU Saint-Etienne
Saint-Etienne, 42100
Antoine DA COSTA, antoine.dacosta@univ-st-etienne.fr
Antoine DA COSTA
- Not yet recruiting
CHRU Strasbourg
Strasbourg, 67091
Laurence JESEL-MOREL, Laurence.JESEL-MOREL@chru-strasbourg.fr
Laurence JESEL-MOREL
- Recruiting
CHU Toulouse
Toulouse, 31059
Philippe MAURY, maury.p@chu-toulouse.fr
Philippe MAURY
- Recruiting
CHRU Tours
Tours, 37044
Fabrice IVANES, F.IVANES@chu-tours.fr
Fabrice IVANES
About this study
Official title: Registre Prospectif français Des Morts Subites Chez Des Sportifs Jeunes
The increased risk of sudden cardiac arrest (SCA) or sudden cardiac death (SCD) related to vigorous physical activity is well-documented. Currently, for young victims (under 35 years) of SCA/SCD, no etiology is found in 40 to 50% of cases after a standard medical assessment, leading to two important consequences. For the victim's family, it is difficult to understand and accept this tragic event, and the risk of it occurring in another family member is a source of concern. Medically, the absence of a known cause limits the ability to effectively prevent such events.
The RESOUDRE study will be a national, prospective, observational registry of young victims (12-35 years) of sports-related SCA/SCD. All cases will undergo the recommended etiological assessment, including autopsy for SCA cases, along with whole exome genetic analysis and toxicological testing. In the event a genetic pathology is identified, a genetic evaluation will be offered to other family members, and appropriate medical care will be provided if necessary. The results of this study could significantly reduce the number of unexplained sport-related SCA/SCD cases and aid in preventing these incidents among affected families.
Read the detailed description
Background:
The beneficial effects of moderate physical activity on health are well-established. However, it is also well-proven that intense sports participation increases the risk of cardiovascular events by 2.4 to 4.5 times before the age of 35 in individuals with known or unknown heart conditions. Sudden cardiac arrest (SCA), sometimes leading to sudden cardiac death (SCD), is the most dramatic event linked to sports.
Before the age of 35, sports-related SCA/SCD is rare, occurring in 0.7 to 2.7 per 100,000 athletes, which amounts to approximately 80 cases per year according to two French prospective studies. Despite its rarity, these events are often traumatic and highly publicized, presenting a significant public health and safety concern. Non-traumatic sports-related SCA/SCD is primarily of cardiovascular origin, irrespective of the level of sports participation. In most cases, SCA results from ventricular arrhythmia caused by known or undiagnosed arrhythmogenic cardiovascular disease, which varies by the victim's age. After the age of 35, atheromatous coronary artery disease accounts for 80-85% of cases. However, before the age of 35, a wider range of etiologies are observed. Arrhythmogenic genetic heart diseases-structural (e.g., arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy) or non-structural (e.g., channelopathies)-are the most frequent causes. Congenital abnormalities, particularly anomalous connection of coronary artery, represent the second most common cause. Acquired heart diseases, such as fibrous scars (mainly post-myocarditis) and atheromatous coronary lesions, are less frequently involved. In this younger population, classical autopsy often fails to determine the cause in more than 40% of cases, leading to the term "sudden arrhythmic syndrome".
Few prospective studies have combined classical autopsy with systematic genetic analysis to identify the cause of SCA/SCD in the general young population, with no specific link to sports. One Australian study demonstrated the value of genetic testing, identifying a "clinically relevant" cardiac genetic variant for sudden death in 27% of cases. Moreover, the same pathology was identified in 13% of relatives of the victims who underwent clinical and genetic screening. Another small Swedish study (n=15), focusing specifically on channelopathies in cases of negative autopsies, revealed the disease in 40% of victims' families through genetic analysis.
Additionally, the role of acute or chronic toxic substance intake has been suggested, albeit without formal proof, as a factor promoting sports-related SCA/SCD. Toxicological screening is thus recommended as part of the etiological assessment. Including toxicological analysis alongside other etiological evaluations could help clarify the impact of illicit substances on sports-related SCA/SCD.
Justifications for the Study:
No prospective study has systematically combined the recommended hospital assessment in cases of successful resuscitation or the recommended medical autopsy in the event of death with global genetic and toxicological analyses in victims of sports-related SCA/SCD.
This combined approach is justified for several reasons. First, it would enhance our understanding of the etiologies of these events. Notably, so-called idiopathic left ventricular hypertrophy is found in more than 10% of sports-related SCD cases following classical autopsies. Further genetic exploration could help determine whether these anatomical forms are pathological. Additionally, many arrhythmic cardiac diseases are associated with an elevated risk of sports-related SCA/SCD. While arrhythmogenic right ventricular cardiomyopathy is well-documented, other forms of disease are characterized by areas of fibrosis or fatty infiltration in the myocardium, often due to genetic mutations affecting intercellular desmosomes. Comprehensive genetic testing, including whole exome sequencing, could clarify the contribution of various arrhythmogenic heart diseases to unexplained sports-related SCA/SCD.
Improving this knowledge will benefit ongoing discussions about enhancing the content and effectiveness of pre-participation screening for athletes. Moreover, identifying the cause of SCA/SCD is critical for the victims and their families. Understanding the cause may help families come to terms with the event and assist in preventing recurrence for successfully resuscitated individuals. Furthermore, since most hereditary heart diseases follow an autosomal dominant inheritance pattern, each first-degree relative has a 50% chance of carrying the same genetic mutation. Predictive testing, clinical assessment, and, if necessary, preventive treatment can be offered to these family members to reduce the risk of arrhythmic events.
Statistical Analysis:
Data analyses will be performed using specialized software, with a significance threshold set at 5%. Hypotheses will be formulated bilaterally.
A descriptive analysis of the collected population data will be conducted. Qualitative variables will be presented as numbers and percentages, while quantitative variables will be described using the mean, standard deviation, median, interquartile range, minimum, and maximum values.
For the primary analysis of the main outcome, the cause of sports-related SCA/SCD will be described in terms of numbers and percentages, along with the corresponding 95% confidence intervals.
For the secondary analyses, the judgment criteria, both overall and by vital status (survived or deceased), will be described in numbers and percentages, with 95% confidence intervals.
- Conditions
- Sudden Cardiac Arrest, Sudden Cardiac Death
- Being tested
- Whole exome sequencing to detect myocardial genetic mutations (SCA group only)
- Keywords
- Sport related sudden cardiac arrest, Sport related sudden cardiac death, Young athlete, Etiological Diagnosis, Autopsy, Genetic, Toxicology, Hereditary Cardiac disease, Prevention
- Medical subject headings
- Death, Sudden, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whole exome sequencing to detect myocardial genetic mutations (SCA group only)Genetic
Whole exome sequencing to detect myocardial genetic mutations
| Study group | Role | What they receive |
|---|---|---|
| Victims of sport-related sudden cardiac arrest (SCA) : resuscitated SCA and non-resuscitated SCA | Following a sport-related sudden cardiac arrest (SCA), resuscitation attempts are frequently made due to the high likelihood of witnesses at the scene. These resuscitation efforts are successful in more than 40% of cases. The study population will therefore be divided into two groups: a group of resuscitated SCA victims (SCA group) and a group of non-resuscitated or unsuccessfully resuscitated victims (SCD group).
The RESOUDRE study is an observational study focusing on individuals who have experienced SCA. Depending on the outcome-whether the individual survives or not-the etiological assessment will differ. While the study design refers to two distinct groups for clarity, they represent a single population, and no statistical comparison between the two groups will be made. Receives: Genetic: Whole exome sequencing to detect myocardial genetic mutations (SCA group only) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of the Cause of Sports-Related Cardiorespiratory Arrest in a Young, Healthy Population
The results for each identified cause of sports-related cardiorespiratory arrest will be presented as the total number of cases (n) and the percentage of the total cases. A 95% confidence interval will also be provided.
Measured: Through study completion, approximately 39 months
Secondary outcomes (5)
Evaluation of the Contribution of Medical Autopsy in Identifying the Etiology of Sports-Related SCA
Results will be presented as the total number of cases (n) and the percentage of the total cases, with a 95% confidence interval.
Measured: 3 to 6 months after the event
Evaluation of the Contribution of Classical Genetic Analysis in Identifying the Etiology of Sports-Related Cardiorespiratory Arrest
The results will be presented as the total number of cases (n) and the percentage of the total cases, with a 95% confidence interval.
Measured: 3 to 6 months after the event
Evaluation of the Contribution of Whole Exome Sequencing in Identifying the Etiology of Sports-Related Cardiorespiratory Arrest
Results will be presented as the total number of cases (n) and the percentage of the total cases, with a 95% confidence interval.
Measured: 24 to 30 months after the event
Evaluation of the Contribution of Toxicological Analysis in Identifying the Etiology of Sports-Related Cardiorespiratory Arrest
Results will be presented as the total number of cases (n) and the percentage of the total cases, with a 95% confidence interval.
Measured: 3 to 6 months after the event
Evaluation of the Familial Transmission of Hereditary Cardiovascular Pathologies Detected
Results will be presented as the total number of cases (n) and the percentage of the total cases, with a 95% confidence interval.
Measured: 3 to 12 months after the event.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start11 Oct 2024
- Primary completion11 Jan 2028 (estimated)
- Study completion11 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sudden Cardiac ArrestStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rennes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Frédéric SCHNELL, Principal investigator, Study Principal Investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06642168
- Sponsor's protocol ID
- 35RC19_8911_RESOUDRE
- Acronym
- RESOUDRE
- Status last verified
- Aug 2026
- First submitted
- 8 Oct 2024
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Registre Prospectif français Des Morts Subites Chez Des Sportifs Jeunes
- ClinicalTrials.gov ID
- NCT06642168
- Acronym / sponsor ID
- RESOUDRE / 35RC19_8911_RESOUDRE
- Conditions
- Sudden Cardiac Arrest, Sudden Cardiac Death
- Keywords
- Sport related sudden cardiac arrest, Sport related sudden cardiac death, Young athlete, Etiological Diagnosis, Autopsy, Genetic, Toxicology, Hereditary Cardiac disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Rennes University HospitalUniversity, hospital or other
- Study start
- 11 Oct 2024 (actual)
- Primary completion
- 11 Jan 2028 (estimated)
- Study completion
- 11 Jan 2028 (estimated)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The increased risk of sudden cardiac arrest (SCA) or sudden cardiac death (SCD) related to vigorous physical activity is well-documented. Currently, for young victims (under 35 years) of SCA/SCD, no etiology is found in 40 to 50% of cases after a standard medical assessment, leading to two important consequences. For the victim's family, it is difficult to understand and accept this tragic event, and the risk of it occurring in another family member is a source of concern. Medically, the absence of a known cause limits the ability to effectively prevent such events.
The RESOUDRE study will be a national, prospective, observational registry of young victims (12-35 years) of sports-related SCA/SCD. All cases will undergo the recommended etiological assessment, including autopsy for SCA cases, along with whole exome genetic analysis and toxicological testing. In the event a genetic pathology is identified, a genetic evaluation will be offered to other family members, and appropriate medical care will be provided if necessary. The results of this study could significantly reduce the number of unexplained sport-related SCA/SCD cases and aid in preventing these incidents among affected families.
Detailed description
Background:
The beneficial effects of moderate physical activity on health are well-established. However, it is also well-proven that intense sports participation increases the risk of cardiovascular events by 2.4 to 4.5 times before the age of 35 in individuals with known or unknown heart conditions. Sudden cardiac arrest (SCA), sometimes leading to sudden cardiac death (SCD), is the most dramatic event linked to sports.
Before the age of 35, sports-related SCA/SCD is rare, occurring in 0.7 to 2.7 per 100,000 athletes, which amounts to approximately 80 cases per year according to two French prospective studies. Despite its rarity, these events are often traumatic and highly publicized, presenting a significant public health and safety concern. Non-traumatic sports-related SCA/SCD is primarily of cardiovascular origin, irrespective of the level of sports participation. In most cases, SCA results from ventricular arrhythmia caused by known or undiagnosed arrhythmogenic cardiovascular disease, which varies by the victim's age. After the age of 35, atheromatous coronary artery disease accounts for 80-85% of cases. However, before the age of 35, a wider range of etiologies are observed. Arrhythmogenic genetic heart diseases-structural (e.g., arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy) or non-structural (e.g., channelopathies)-are the most frequent causes. Congenital abnormalities, particularly anomalous connection of coronary artery, represent the second most common cause. Acquired heart diseases, such as fibrous scars (mainly post-myocarditis) and atheromatous coronary lesions, are less frequently involved. In this younger population, classical autopsy often fails to determine the cause in more than 40% of cases, leading to the term "sudden arrhythmic syndrome".
Few prospective studies have combined classical autopsy with systematic genetic analysis to identify the cause of SCA/SCD in the general young population, with no specific link to sports. One Australian study demonstrated the value of genetic testing, identifying a "clinically relevant" cardiac genetic variant for sudden death in 27% of cases. Moreover, the same pathology was identified in 13% of relatives of the victims who underwent clinical and genetic screening. Another small Swedish study (n=15), focusing specifically on channelopathies in cases of negative autopsies, revealed the disease in 40% of victims' families through genetic analysis.
Additionally, the role of acute or chronic toxic substance intake has been suggested, albeit without formal proof, as a factor promoting sports-related SCA/SCD. Toxicological screening is thus recommended as part of the etiological assessment. Including toxicological analysis alongside other etiological evaluations could help clarify the impact of illicit substances on sports-related SCA/SCD.
Justifications for the Study:
No prospective study has systematically combined the recommended hospital assessment in cases of successful resuscitation or the recommended medical autopsy in the event of death with global genetic and toxicological analyses in victims of sports-related SCA/SCD.
This combined approach is justified for several reasons. First, it would enhance our understanding of the etiologies of these events. Notably, so-called idiopathic left ventricular hypertrophy is found in more than 10% of sports-related SCD cases following classical autopsies. Further genetic exploration could help determine whether these anatomical forms are pathological. Additionally, many arrhythmic cardiac diseases are associated with an elevated risk of sports-related SCA/SCD. While arrhythmogenic right ventricular cardiomyopathy is well-documented, other forms of disease are characterized by areas of fibrosis or fatty infiltration in the myocardium, often due to genetic mutations affecting intercellular desmosomes. Comprehensive genetic testing, including whole exome sequencing, could clarify the contribution of various arrhythmogenic heart diseases to unexplained sports-related SCA/SCD.
Improving this knowledge will benefit ongoing discussions about enhancing the content and effectiveness of pre-participation screening for athletes. Moreover, identifying the cause of SCA/SCD is critical for the victims and their families. Understanding the cause may help families come to terms with the event and assist in preventing recurrence for successfully resuscitated individuals. Furthermore, since most hereditary heart diseases follow an autosomal dominant inheritance pattern, each first-degree relative has a 50% chance of carrying the same genetic mutation. Predictive testing, clinical assessment, and, if necessary, preventive treatment can be offered to these family members to reduce the risk of arrhythmic events.
Statistical Analysis:
Data analyses will be performed using specialized software, with a significance threshold set at 5%. Hypotheses will be formulated bilaterally.
A descriptive analysis of the collected population data will be conducted. Qualitative variables will be presented as numbers and percentages, while quantitative variables will be described using the mean, standard deviation, median, interquartile range, minimum, and maximum values.
For the primary analysis of the main outcome, the cause of sports-related SCA/SCD will be described in terms of numbers and percentages, along with the corresponding 95% confidence intervals.
For the secondary analyses, the judgment criteria, both overall and by vital status (survived or deceased), will be described in numbers and percentages, with 95% confidence intervals.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Victims of sport-related sudden cardiac arrest (SCA) : resuscitated SCA and non-resuscitated SCA | – | Genetic: Whole exome sequencing to detect myocardial genetic mutations (SCA group only)Following a sport-related sudden cardiac arrest (SCA), resuscitation attempts are frequently made due to the high likelihood of witnesses at the scene. These resuscitation efforts are successful in more than 40% of cases. The study population will therefore be divided into two groups: a group of resuscitated SCA victims (SCA group) and a group of non-resuscitated or unsuccessfully resuscitated victims (SCD group). The RESOUDRE study is an observational study focusing on individuals who have experienced SCA. Depending on the outcome-whether the individual survives or not-the etiological assessment will differ. While the study design refers to two distinct groups for clarity, they represent a single population, and no statistical comparison between the two groups will be made. |
Who may qualify
- Ages
- 12 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- The study will include French victims of sports-related SCA/SCD between the ages of 12 and 35, as well as their first-degree relatives over 12 years of age, when applicable.
Key inclusion criteria (11 listed)
- Victims of SCA:
- First-Degree Relatives:
- For resuscitated SCA cases, individuals weighing less than 20 kg
- Victims or legal representatives who are subject to legal protection or deprived of their liberty
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whole exome sequencing to detect myocardial genetic mutations (SCA group only)Whole exome sequencing to detect myocardial genetic mutations | Genetic | Victims of sport-related sudden cardiac arrest (SCA) : resuscitated SCA and non-resuscitated SCA |
Primary outcome
Identification of the Cause of Sports-Related Cardiorespiratory Arrest in a Young, Healthy Population
Time frame: Through study completion, approximately 39 months
The results for each identified cause of sports-related cardiorespiratory arrest will be presented as the total number of cases (n) and the percentage of the total cases. A 95% confidence interval will also be provided.
5 secondary outcomes
Evaluation of the Contribution of Medical Autopsy in Identifying the Etiology of Sports-Related SCA
Time frame: 3 to 6 months after the event
Evaluation of the Contribution of Classical Genetic Analysis in Identifying the Etiology of Sports-Related Cardiorespiratory Arrest
Time frame: 3 to 6 months after the event
Evaluation of the Contribution of Whole Exome Sequencing in Identifying the Etiology of Sports-Related Cardiorespiratory Arrest
Time frame: 24 to 30 months after the event
Evaluation of the Contribution of Toxicological Analysis in Identifying the Etiology of Sports-Related Cardiorespiratory Arrest
Time frame: 3 to 6 months after the event
Evaluation of the Familial Transmission of Hereditary Cardiovascular Pathologies Detected
Time frame: 3 to 12 months after the event.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Sudden Cardiac Arrest
RecruitingPhase 4
Epinephrine Dose: Optimal Versus Standard Evaluation Trial
Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest
Recruiting
Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America
Cardiac Arrest, Sudden Cardiac Arrest
RecruitingObservational study
Mitral Valve Prolapse Arrhythmic Risk
Mitral Valve Prolapse, Ventricular Arrhythmias and Cardiac Arrest
RecruitingObservational study
Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
Sudden Cardiac Arrest, Sudden Cardiac Death
RecruitingObservational study
Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD
Coronary Arterial Disease (CAD), Sudden Cardiac Arrest
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frédéric SCHNELL principal investigator
Study Principal Investigator
26 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sudden Cardiac Arrest and Sudden Cardiac Death, run by Rennes University Hospital at 26 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 26 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Frédéric SCHNELL (0299284133, frederic.schnell@chu-rennes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identification of the Cause of Sports-Related Cardiorespiratory Arrest in a Young, Healthy Population (time frame: Through study completion, approximately 39 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026; AzTrials last refreshed its copy on 26 Oct 2026.